OrthoPediatrics (FRA:2X7) Research & Development: €7.7 Mil (TTM As of Mar. 2026)


FRA:2X7 OrthoPediatrics Corp FRA:2X7
77 GF Score
Price €16.30
GF Value €28.14
! 5 Warning Signs
View Full Analysis

What is OrthoPediatrics Research & Development?

OrthoPediatrics FRA:2X7 +0.62% 77 Research & Development is €7.7 Mil as of Mar. 2026. GuruFocus rates FRA:2X7 with a GF Score™ of 77/100 and a GF Value™ of €28.14. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. OrthoPediatrics's Research & Development for the three months ended in Mar. 2026 was €1.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €7.7 Mil.

OrthoPediatrics  (FRA:2X7) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

OrthoPediatrics Research & Development Related Terms

OrthoPediatrics Research & Development Historical Data

* Premium members only.

The historical data trend for OrthoPediatrics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OrthoPediatrics Research & Development Chart

OrthoPediatrics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.91 7.98 9.99 10.54 7.77

OrthoPediatrics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.18 1.87 1.99 1.93 1.93
FRA:2X7
77GF Score
OrthoPediatrics Corp FRA:2X7
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OrthoPediatrics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €7.7 Mil mean?
OrthoPediatrics (FRA:2X7) has a Research & Development of €7.7 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on OrthoPediatrics and its competitors.
Is OrthoPediatrics' Research & Development too high?
OrthoPediatrics' current Research & Development is €7.7 Mil. Overall, OrthoPediatrics has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does OrthoPediatrics' Research & Development compare to LAB and CATX?
OrthoPediatrics' Research & Development of €7.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on OrthoPediatrics and its competitors. OrthoPediatrics's current Research & Development is €7.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrthoPediatrics stock overvalued right now?
OrthoPediatrics (FRA:2X7) has a current Research & Development of €7.7 Mil. The stock's GF Value™ is €28.14, compared to a current price of €16.30 — trading 42.1% below its estimated fair value. The current Research & Development is €7.7 Mil. OrthoPediatrics' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For OrthoPediatrics (FRA:2X7), the current Research & Development is €7.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OrthoPediatrics (FRA:2X7) Overvalued in 2026?

Based on GuruFocus' analysis, OrthoPediatrics stock appears to be undervalued. The current stock price of €16.30 is trading 42.1% below its estimated GF Value™ of €28.14.

Key valuation signals for FRA:2X7:

  • Research & Development: €7.7 Mil
  • GF Value™: €28.14 vs. price of €16.30 (42.1% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the FRA:2X7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OrthoPediatrics Business Description

Other Exchanges KIDS:USA
Address 2850 Frontier Drive, Warsaw, IN, USA, 46582
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
77GF Score

Get the complete analysis for FRA:2X7

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.30
Price
€28.14
GF Value